The core value of L-aspartic acid in the pharmaceutical field stems from its role in two key metabolic pathways: acting as a carrier to facilitate electrolyte entry into cells-thereby protecting the myocardium and liver-and participating in the ornithine cycle to help lower blood ammonia levels and alleviate fatigue.
Liver Protection: Ammonia Detoxification and Enhancement of Liver Function
The liver is central to human metabolism; when liver function is impaired, elevated blood ammonia levels can trigger a cascade of problems. L-aspartic acid plays a pivotal role here by participating in the ornithine cycle, promoting the conversion of ammonia and carbon dioxide into urea for excretion. This effectively reduces ammonia and carbon dioxide levels in the blood and enhances liver function.
Based on this mechanism, L-aspartic acid and its derivatives have become key components in adjuvant therapies for various liver diseases:
Potassium-Magnesium Aspartate: Utilizing L-aspartic acid as a carrier to deliver potassium and magnesium ions to hepatocytes, this drug is used as an adjuvant treatment for conditions such as acute and chronic hepatitis, liver cirrhosis, and hepatic encephalopathy.
Ornithine Aspartate (LOLA): Clinically used to treat hyperammonemia caused by acute or chronic liver disease, this drug is particularly valuable in the emergency management of hepatic coma. Recent research indicates that combining LOLA with therapeutic plasma exchange may yield a synergistic ammonia-lowering effect in pediatric patients with acute liver failure.
Notably, a 2024 study published in *Pharmacological Research* by Professor Huang Ling's team at Hainan University found that oral administration of L-aspartic acid in mice effectively reversed carbon tetrachloride-induced acute liver injury and liver fibrosis. The study demonstrated that L-aspartic acid protects the liver by remodeling the balance of cholesterol and bile acid metabolism and restoring mitochondrial metabolic function. This discovery opens new possibilities for the application of L-aspartic acid in treating liver fibrosis.
Fatigue Recovery: From Exercise-Induced Fatigue to Chronic Fatigue
The fatigue-alleviating effects of L-aspartic acid are also closely linked to ammonia metabolism. The accumulation of ammonia in the body during exercise or high-intensity physical activity is a significant factor contributing to fatigue. L-Aspartate accelerates ammonia clearance by promoting the urea cycle while simultaneously enhancing myocardial contractility and reducing oxygen consumption, thereby alleviating fatigue and improving exercise endurance.
In recent years, this application has expanded to encompass more complex chronic fatigue conditions. A study published in 2025 in an NIH-affiliated journal revealed a significant downregulation of the aspartate metabolic pathway in the muscle tissue of patients with ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) and Long COVID; the research team proposed that a combination of L-ornithine and L-aspartate (LOLA) serves as a potential therapeutic candidate for alleviating these metabolic symptoms. This finding extends the application of L-aspartate beyond traditional fatigue recovery into the emerging field of chronic fatigue disorders.